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ABSTRACT
INTRODUCTION: The iron overload and the development of secondary hemosiderosis in patients with 
β-thalassemia major (β-TM) lead to organ damages, including kidney disorders from early childhood. Con-
temporary urinary markers such as neutrophil gelatinase-association lipocalin (NGAL), β2-microglobulin 
(β2-MG), and N-acetyl-β-D-glucosaminidase (NAG) could be a useful tool for clinicians in diagnosis of ear-
ly tubular lesions. 
AIM: The aim of this article is to make an assessment of contemporary urine biomarkers β2-microglobulin, 
neutrophil gelatinase-associated lipocalin, and N-acetyl-beta-D-glucosaminidase in the diagnosis of early 
renal injury in patients with β-TM.
MATERIALS AND METHODS: The current study was conducted by examining 44 patients with 
β-thalassemia major and 30 controls. All participants were tested for NGAL, β2-MG, and NAG in the first 
sample morning urine using ELISA method. 
RESULTS: The results show statistically significant differences between the two examined groups in uri-
nary NGAL. 
CONCLUSION: Urinary NGAL indicates subclinical kidney injury when the tubular reabsorption of mol-
ecules is impaired.
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INTRODUCTION
Patients with β-thalassemia major (β-TM) are 
characterized by co-morbidity and poor quality of 
life. Iron overload and the development of second-
ary hemosiderosis from early childhood lead to or-
gan damages, including renal disorders. Some of pa-
tients develop low-grade proteinuria and albumin-
uria, while others develop tubular disorders-hyper-
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Chronic anemia and hypoxia reduce peripher-
al vascular resistance, increase renal plasma flow and 
intraglomerular pressure. Hyperfiltration with mac-
romolecule transudation occurs, as well as low-grade 
proteinuria. The proteinuria is one of the risk fac-
tors of renal impairment. It activates genes respon-
sible for the synthesis of fibrogenic cytokines. One of 
these cytokines is TGF-β1, which is directly related 
to the pathogenesis of tubulointerstitial fibrosis (10).
Chelators can lead to impaired renal function 
from a transient slight increase in serum creatinine 
to acute renal impairment (11,12). Tanji et al. (2001) 
report that deferasirox increases serum creatinine 
as a result of renal plasma reduction and glomeru-
lar filtration in some thalassemic patients. The ef-
fects of deferasirox on the expression of cyclooxygen-
ase 2 (COX-2), an enzyme in the synthesis of pros-
taglandins, have been investigated by the authors. 
They state that COX-2 expression and prostaglandin 
synthesis, mediators of inflammation, are increased 
upon treatment with deferasirox (13). Chelators af-
fect the arachidonic acid cascade and the produc-
tion of prostaglandins with subsequent imbalance 
between vasodilators and vasoconstrictors. Tubulo-
glomerular feedback is activated, production of ade-
calciuria, hyperphosphaturia, hyperuricosuria, ami-
noaciduria, glucosuria (1,2,3). Elevated levels of uro-
proteins β2-microglobulin (β2-MG), neutrophil gela-
tinase-associated lipocalin (NGAL), N-acetyl-beta-
D-glucosaminidase (NAG), Tamm Horsfall protein 
have been reported (4).
Several factors are responsible for impaired re-
nal function in patients with β-TM: shortened eryth-
rocyte life, iron deposits in tissues, and iron chelation 
therapy (5,6).
The increased erythrocyte turnover and the 
need for frequent hemotransfusions results in the de-
position of hemosiderin in the glomeruli, proximal 
tubules and interstitium with subsequent renal dam-
age. Hashemieh et al. (2017) report that renal hemo-
siderosis is prevalent in patients with β-TM (7). The 
accumulated free intracellular iron is toxic for the 
tissues. It generates reactive oxygen species (ROS), 
which: damage cell membranes by lipid peroxidation; 
lead to destruction of cell organelles (mitochondria); 
disrupt mitochondrial respiratory chains, stimulate 
the development of fibrosis. ROS increase the risk of 
neoplasia such as hepatoma, and infections. Apopto-
sis of the cell occurs (Fig. W1) (8). 
Fig. 1. Pathological mechanism and consequences of iron overload (9)
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nosine and adenosine triphosphate is increased. This 
results in vasoconstriction of afferent pre-glomeru-
lar arterioles with subsequent reduction of glomeru-
lar filtration (5).
It is known that chronic kidney disease (CKD) 
very often is not diagnosed before the onset of an 
end-stage renal disease (ESRD) due to the lack of sig-
nificant complaints of patients. The therapeutic op-
tions are limited in cases of advanced renal impair-
ment. The practice of early examination and treat-
ment can slow down the progression of CKD. This 
determines the growing interest of clinicians to look 
for new, non-invasive and sensitive markers of renal 
dysfunctions.
Neutrophil gelatinase-associated lipocalin is a 
protein with molecular mass of 25 kDa. It was de-
scribed for the first time in 1993 (15,16). In a state of 
stress (infection, inflammation, ischemia, neoplas-
tic proliferation) there is a pronounced expression in 
the damaged epithelial cells in both the kidney and 
the colon, as well as in the liver and the lungs (17). 
Neutrophil gelatinase-associated lipocalin is filtered 
through the glomerulus and is largely reabsorbed in 
the proximal tubule. Neutrophil gelatinase-associat-
ed lipocalin excretion is a result of renal injury affect-
ing reabsorption in proximal tubule and/or inducing 
de novo synthesis of NGAL in the distal tubule.
Neutrophil gelatinase-associated lipocalin is a 
renal troponin, an early biomarker and predictor of 
Fig. 2. β-thalassemia and the nephron (14)
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renal impairment in cases of sepsis, administration 
of nephrotoxic drugs, contrast-induced nephropa-
thy, urinary infections, glomerulonephritis, diabet-
ic nephropathy, lupus nephropathy, and transfusion-
dependent anemias (18,19,20). Velat Sen et al. (2015) 
indicate NGAL as a potential marker in screening or 
renal dysfunctions in patients with β-TM (4).
N-acetyl-β-D-glucosaminidase is a lysosomal 
enzyme in the proximal tubules of kidneys and can 
be used as a marker of proximal tubular damage and 
nephrotoxity. It does not filter through the glomer-
ular basement membrane due to its high molecular 
weight of about 130-140 kDa. Urinary NAG testing is 
a rapid, non-invasive method for determining renal 
tubular function (21).
Beta 2-microglobulin is a protein with molecu-
lar mass of 11.58 кDa which is found in the cell mem-
brane of all eukaryotic cells. It is completely filtered 
and in 99.9% is reabsorbed in the proximal tubule 
(22).
AIM
The aim of this study is to make an assess-
ment of the contemporary urine biomarkers β2-MG, 
NGAL, and NAG in the diagnosis of early renal inju-
ry in patients with β-TM.
MATERIALS AND METHODS
A total of 44 patients with β-TM aged between 
7 and 57 years of whom 18 children (12 girls and 6 
boys) and 26 adults (14 women and 12 men) partici-
pated in our study. The diagnosis of β-TM was con-
firmed by hemoglobin electrophoresis. 
Inclusion criteria: Patients with β-TM with 
signed informed consent were eligible for the 
study. 
Exclusion criteria: Patients with β-TM and di-
abetes mellitus, chronic glomerulonephritis, uncon-
trolled arterial hypertension, acute urinary infec-
tions, pregnancy, cancer disease, taking nephrotic 
drugs, and application of iodine-based contrast ma-
terials in the last month were not eligible.
The control group consisted of 30 healthy par-
ticipants aged between 7 and 45 years of whom 13 
were children (9 girls and 4 boys) and 17 were adults 
(12 women and 5 men). None of them reported about 
hereditary anemia, requiring regular blood transfu-
sions. They did not have cardiovascular, renal, en-
docrine and/or cancer disease, did not abuse alcohol 
and narcotic substances. During the study the wom-
en were not pregnant, did not breastfeed, did not take 
contraceptive drugs, and were not menstruating. The 
study was conducted in the period between Septem-
ber 2018 and August 2019.
Measurement of the uroproteins β2-MG, 
NGAL, and NAG of patients and healthy controls 
was performed by first sample morning urine cen-
trifuged at 3000 rpm, after that the supernatant was 
separated and frozen at а temperature –20oC un-
til the start of study. The biomarkers were measured 
with immunosorbent assay (ELISA).
Statistical Analysis
Descriptive and analytical methods were 
used. The significance level for differences be-
tween the studied groups was set to р≤0.05.
The strength of the correlation between the 
variables is based on the Pearson coefficient (r). The 
levels are determined as statically significant for val-
ues of r >0.5 and <r=0.7; for 0.7 <r=0.9 as strong and 
for r>0.9—very strong.
RESULTS
We selected the reference group according to re-
quirements of IFCC (International Federation of Clini-
cal Chemistry) and developed reference ranges of the 
laboratory parameters studied and presented in the 
dimensions indicated by us: β2-microglobulin/creat-
inine ratio mg/mol, NGAL/creatinine ratio ng/mol., 
NAG/creatinine ratio U/mol (Table 1).
Biomarker Minimum Maximum Mean SD
β2-MG/creatininе 0 8.3650 2.531000 ± 2.1676115 
NGAL/creatininе 0 0.0190 0.002233 ± 0.0037268 
NAG/creatininе 0.0002 0.1800 0.018363 ± 0.0353029 
Table 1. Reference ranges of the studied urinary biomarkers/creatinine ratios of healthy controls 
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The correlations between parameters β2-MG/
creatininе, NGAL/creatininе, NAG/creatininе ratios 
determined by the Mann-Whitney U-Test are pre-
sented at Table 2.
A positive correlation has been demonstrated 
between β2-MG/creatinine and NGAL/creatinine ra-
tios (p=0.050, r=0.297) (Table 3, Fig. 3).
DISCUSSION
For the first time in Bulgaria a study was done 
investigating tubular disorders in patients with 
β-TM. Contemporary, non-invasive, sensitive and 
specific urinary biomarkers were measured, which 
provides additional information about the tubulop-
athies in thalassemic patients. There was a statisti-
cally significant difference in the NGAL/creatininе 
ratio between patients and controls. Our results con-
firmed those in the world literature reporting signif-
icantly high levels of urinary NGAL in patients with 
β-TM (4).
Neutrophil gelatinase-associated lipocalin like 
β2-MG indicates very early damages of the proximal 
tubule when the tubular reabsorption of soluble sub-
stances is impaired. The urine NGAL can be used as 
a reliable marker for subclinical renal injury in thal-
assemic patients. N-acetyl-β-D-glucosaminidase is a 
slightly later marker in diagnosing of tubulopathies. 
Their detection in the urine indicates cell lysis. 
We found early disorders of tubular function 
before the onset of cell death, which makes the study 
Biomarker Controls Patients U test/Z P
β2-MG/creatininе 2.5310 ± 2.1676 3.393 ± 2.7238 -1.59 0.116
NGAL/creatininе 0.0022 ± 0.0037 0.0106 ± 0.040 2.25 0.028
NAG/creatininе 0.0183 ± 0.0353 0.0283 ± 0.0706 -0.89 0.375
Table 2. Mann-Whitney U-Test





































Table 3. Pearson correlation
Fig. 3. Correlation between β2-MG/creatinine and NGAL/
creatinine ratios
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relevant, further supplementing existing bodies of 
knowledge on the matter with additional support-
ing data. 
CONCLUSION
The development of the renal inflammatory 
process affects primarily the tubule cells. This could 
be the result of the damage done on various levels by 
oxidative stress. The urinary molecules β2-MG and 
NGAL are an evidence of disorders in the reabsorp-
tion of substances. More severe impairments in the 
tubules manifest during high levels of NAG. Know-
ing the pathophysiology of tubulopathies in patients 
with β-ТМ and their diagnosis using non-invasive 
ways will give clinicians more opportunities to pre-
dict the onset of the early renal damage in order to 
counteract with new therapeutic schemes in the early 
stages of the disease. 
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